Business Development
Partnerships
Out Licensing
Lipocine will entertain partnering conversations for oral testosterone undecanoate in non-partnered markets with pharmaceutical companies that have a strong history in driving adoption of new pharmaceutical products.
Oral testosterone undecanoate (TLANDO® in U.S.) is our commercial product partnered in various territories.
In Licensing
Lipocine is looking for innovative products that will strengthen our metabolic and neuroendrocrine disorder treatment portfolio. These products can be in various development phases.
Testosterone Undecanoate
Lipocine is open to entertaining partnering discussions on our pipeline assets in various stages of development with a leading pharma company with infrastructure, expertise and presence in major markets or planning to maximize the global potential for the applicable therapeutic category.
Partnered Markets | Partners | Brand | Use |
|---|---|---|---|
USA | Verity Pharma | TLANDO® | Testosterone replacement therapy |
Canada | Verity Pharma | TLANDO® | Testosterone replacement therapy |
South Korea | SPC | TBD | Testosterone replacement therapy |
Brazil | Aché Laboratórios Farmacêuitcos S.A | TBD | Testosterone replacement therapy |
Gulf Cooperation Council
(GCC): Saudi Arabia, Kuwait,
the United Arab
Emirates (UAE), Qatar, Bahrain,
and Oman | Pharmalink | TBD | Testosterone replacement therapy |